Imaging Neuroinflammation in Hepatic Encephalopathy: Comparative Efficacy of Bifidobacterium and Fecal Microbiota Transplantation

Study Background and Research Question

Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome arising from advanced chronic liver failure, characterized by cognitive dysfunction and neuroinflammation. Increasing evidence suggests that the gut–liver–brain axis plays a fundamental role in HE pathogenesis, with gut microbiota composition influencing both systemic and neuroinflammatory responses (Cryan et al., 2020; Bajaj 2019). However, the mechanistic details connecting gut dysbiosis to central nervous system inflammation remain incompletely understood. The reference study by Kong et al. (European Journal of Neuroscience, 2025) addresses this gap by evaluating two gut-targeted interventions—Bifidobacterium (BIF) and fecal microbiota transplantation (FMT)—for their capacity to mitigate neuroinflammation in a rat model of chronic HE, using advanced [18F]PBR146 PET imaging to directly visualize neuroinflammatory processes in vivo.

Key Innovation: Molecular Imaging as a Window into Gut–Brain Therapeutic Efficacy

This study is among the first to employ the TSPO-targeted PET radiotracer [18F]PBR146 for noninvasive, region-specific assessment of neuroinflammation in experimental HE. By integrating advanced imaging with microbiota profiling and behavioral assays, the authors provide a multidimensional evaluation of how gut-targeted therapies modulate not just peripheral but also central inflammatory states. Notably, the research demonstrates that Bifidobacterium supplementation, but not FMT, can significantly inhibit neuroinflammation in specific brain regions of bile duct ligated (BDL) rats—a finding that refines the therapeutic prospects for microbiota-based interventions in HE.

Methods and Experimental Design Insights

• Thirty male rats were assigned to four groups: Sham + normal saline (NS), BDL + NS, BDL + BIF, and BDL + FMT.
• Chronic HE was induced via bile duct ligation (BDL), a validated preclinical model simulating cirrhosis-associated neuroinflammation and cognitive dysfunction.
• Interventions included oral Bifidobacterium or fecal microbiota transplantation, administered following HE model establishment.
• Behavioral analyses, fecal sample collection for microbiota profiling, and micro-PET/CT imaging using [18F]PBR146 were conducted to assess neuroinflammatory states.
• Quantitative data included PET tracer uptake (%ID/g) across the whole brain and anatomically defined regions of interest (ROIs), alongside cytokine profiling (IL-1β, IL-6, IL-10, TNF-α) and histopathological evaluation.

Notably, [18F]PBR146 targets the 18-kDa translocator protein (TSPO), a marker upregulated in activated microglia, making it a robust biomarker for neuroinflammation imaging (Kong et al., 2025).

Core Findings and Why They Matter

1. Bifidobacterium Attenuates Neuroinflammation in HE: While global brain uptake of [18F]PBR146 did not differ significantly among groups, regional analyses revealed that Bifidobacterium administration substantially reduced neuroinflammation in specific brain areas, notably the bilateral accumbens and retrosplenial cortex. This suggests region-dependent effects of gut-targeted interventions on neuroinflammatory processes.

2. FMT Does Not Confer Neuroprotection in This HE Model: Fecal microbiota transplantation failed to reduce neuroinflammation and did not improve behavioral or cytokine profiles in BDL rats. The authors attribute this to possible dysbiosis or suboptimal engraftment, emphasizing that not all microbiota interventions offer equivalent efficacy, particularly in the context of advanced liver disease.

3. Microbiota and Metabolite Shifts Reflect Intervention Outcomes: Microbiota profiling showed distinct compositional shifts associated with each group. For example, the BDL + FMT group was enriched with Enterococcus, Aestuariispira, Lactobacillus, Pseudomonas, and Globicatella, while BDL + BIF rats showed increased Enterorhabdus. These community changes may underlie the differential neuroinflammatory outcomes observed.

4. PET Imaging Enables In Vivo Efficacy Monitoring: The use of [18F]PBR146 PET provided real-time, region-specific insights into microglial activation and neuroinflammation, establishing its value for preclinical screening of gut–brain interventions.

Protocol Parameters

• Bile duct ligation (BDL) induction: Surgical model for chronic HE; confirm cirrhosis and HE phenotype before intervention.
• Bifidobacterium administration: Dose and strain as per validated protocols in neuroinflammation research; administer orally post-HE modeling.
• [18F]PBR146 PET imaging: Perform serial imaging post-intervention; analyze %ID/g uptake across whole brain and specific ROIs.
• Behavioral and cytokine assessments: Integrate open field, maze, or other cognitive tasks with ELISA-based cytokine quantification for comprehensive readouts.
• Microbiota profiling: Collect fecal samples pre- and post-intervention for 16S rRNA sequencing; employ LEfSe and PCoA for analysis.

Comparison with Existing Internal Articles

Internal literature has increasingly highlighted the intersection of gut motility, microbiota modulation, and neuroinflammation. For instance, "Sodium Picosulfate in Translational Neuroinflammation and..." discusses how stimulant laxatives, such as sodium picosulfate, may influence the gut–liver–brain axis, complementing the current study's approach of targeting gut health to modulate brain outcomes. Similarly, "Sodium Picosulfate: Mechanistic Insights and Novel Direct..." explores the use of sodium picosulfate in experimental models of neuroinflammation, alluding to its potential for microbiota-mediated central effects. However, the reference study by Kong et al. is unique in its application of in vivo TSPO PET imaging to quantify neuroinflammation, providing a direct, quantifiable readout of intervention efficacy that goes beyond behavioral and cytokine endpoints.

Moreover, whereas sodium picosulfate's primary mechanism involves electrolyte absorption inhibition and water secretion stimulation in the colon—critical for chronic constipation management and opioid-induced constipation relief (product information)—the current study's findings suggest the broader relevance of gut interventions for neuroinflammatory modulation. This convergence between gut motility agents and microbiota-targeted therapies highlights promising avenues for translational research.

Limitations and Transferability

Several limitations should be considered when extrapolating these findings. First, the lack of significant differences in behavioral and cytokine outcomes may reflect either the specificity of the imaging marker (TSPO) for microglial activation or the relatively short intervention duration. Second, FMT efficacy is highly dependent on donor selection, preparation, and host receptivity, which may not have been optimized in the BDL context. Third, while region-specific PET findings are compelling, whole-brain neuroinflammation metrics did not reach statistical significance (p = 0.053), suggesting the need for larger cohorts or more sensitive quantification methods. Finally, species differences between rodent models and human HE limit direct clinical translation, though the imaging and workflow innovations remain highly informative for preclinical research.

Why this cross-domain matters, maturity, and limitations

The convergence of gut–brain axis research with advanced neuroimaging methods opens new opportunities for dissecting the causal pathways linking microbiota, intestinal function, and central nervous system health. While stimulant laxatives such as sodium picosulfate are established for constipation treatment, their emerging roles in modifying the gut environment may have downstream effects on neuroinflammatory processes, as suggested in recent mechanistic reviews (see also). However, robust evidence for cross-domain therapeutic efficacy—particularly for neuropsychiatric outcomes in liver disease—remains limited, and future studies should integrate both mechanistic and functional outcomes to clarify these links.

Research Support Resources

For laboratories aiming to reproduce or extend these workflows, high-purity reagents are essential. Sodium Picosulfate (SKU B2027) from APExBIO is provided as both a solid and a 10 mM DMSO solution, offering validated solubility and stability parameters suited for preclinical models of gut motility and gut–brain interaction. Researchers studying constipation, gut-liver-brain axis biology, or neuroinflammation may find this reagent useful for integrating gut-modulating protocols alongside microbiota-targeted or imaging-based investigations. As always, this product is for scientific research use only.